Physician profile
David Menchell
NPI 1942224415
$2,625.00
in general payments reported to CMS, 2019-2025
15 companies · $535 in 2025
The $535 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $199 · 2021: $274 · 2022: $108 · 2023: $619 · 2024: $411 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,466 · Education: $98.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,466.45 |
| Education | $98.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $617.94 | 2019-2025 | Dupixent |
| Genzyme Corporation | $484.28 | 2021-2025 | |
| Glaxosmithkline, LLC. | $370.16 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Optinose US, INC. | $215.42 | 2019-2021 | |
| Amgen INC. | $189.05 | 2024-2025 | Tezspire |
| Astrazeneca Pharmaceuticals Lp | $164.64 | 2019-2025 | Tezspire |
| Pfizer INC. | $140.31 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $129.95 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $87.77 | 2025 | Neffy |
| Alk-Abello, INC | $30.12 | 2019 | |
| Mylan Specialty L.P. | $28.21 | 2023 | Yupelri |
| Biocryst US Sales Co., LLC | $25.42 | 2025 | Orladeyo |
| Merck Sharp & Dohme LLC | $24.73 | 2021 | |
| Genentech USA, INC. | $19.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Menchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.